rs6797312 — SERPINI1

SERPINI1 and Stroke Risk — Neuroserpin's Role in Brain Protection

Neuroserpin¹¹ Neuroserpin
encoded by SERPINI1 on chromosome 3q26 is a serine protease inhibitor expressed primarily in neurons. Its principal job is to regulate tissue-type plasminogen activator (tPA)²² tissue-type plasminogen activator (tPA)
the enzyme that dissolves blood clots in the brain but can also damage the blood-brain barrier when unchecked. The rs6797312 variant sits in intron 1 of SERPINI1 and does not change the protein directly, but may influence how much neuroserpin the brain produces or when it is expressed. A single case-control study identified the A allele as a risk factor for early-onset ischemic stroke among Caucasian women, while a subsequent European replication study found no association — leaving the evidence at the emerging level.

The Mechanism

When ischemia occurs, tPA activity in the brain rises sharply. Unchecked tPA degrades tight junction proteins and activates matrix metalloproteinase-9 (MMP-9)³³ degrades tight junction proteins and activates matrix metalloproteinase-9 (MMP-9)
both of which increase blood-brain barrier permeability and allow inflammatory cells to flood ischemic tissue. Neuroserpin counteracts this by binding and inhibiting tPA within the central nervous system — a role separate from plasminogen activator inhibitor-1 (PAI-1), which controls tPA systemically. Mice lacking neuroserpin develop larger infarcts, increased BBB leakage, and spontaneous intracerebral hemorrhage⁴⁴ Mice lacking neuroserpin develop larger infarcts, increased BBB leakage, and spontaneous intracerebral hemorrhage
demonstrating that neuroserpin is the brain's primary tPA gatekeeper. It also maintains BBB integrity by limiting MMP-9 activity and preserving structural proteins at the vessel wall⁵⁵ maintains BBB integrity by limiting MMP-9 activity and preserving structural proteins at the vessel wall
an anti-inflammatory action separate from its antiprotease role. The intronic rs6797312 variant may reduce neuroserpin expression in a context- or ancestry-specific way, subtly weakening this brain-protective circuit.

The Evidence

The primary association evidence comes from the Stroke Prevention in Young Women (SPYW) study⁶⁶ Stroke Prevention in Young Women (SPYW) study
a population-based case-control study in Maryland and Washington DC, USA by Cole et al. (2007). The study enrolled 224 women aged 15–49 with first ischemic stroke and 211 age-matched controls⁷⁷ 224 women aged 15–49 with first ischemic stroke and 211 age-matched controls
approximately half of each group were African-American. Among Caucasian women, A allele carriers (genotypes AA and AT combined) had a twofold increased odds of stroke compared to TT carriers⁸⁸ twofold increased odds of stroke compared to TT carriers
OR 2.05, 95% CI not reported; p = 0.023, dominant model. No significant association was found in African-American participants (OR 0.71, p = 0.387), a pattern that may reflect different haplotype backgrounds, linkage disequilibrium structure, or allele frequency differences across ancestries (African A allele frequency ~0.39 vs European ~0.59).

A critical counterpoint: Tjärnlund-Wolf et al. (2011)⁹⁹ Tjärnlund-Wolf et al. (2011)
a Swedish cohort including all subtypes of ischemic stroke examined SERPINI1 genetic variation and found no evidence of association with ischemic stroke¹⁰¹⁰ no evidence of association with ischemic stroke
published as a letter to the Journal of Neurology. The non-replication may reflect differences in stroke subtype composition, sex distribution, age range, or simply limited statistical power in the smaller letter-format study. These conflicting results mean rs6797312's role in stroke risk remains plausible but unconfirmed pending larger, ancestry-stratified studies.

Supporting the biological plausibility: clinical studies show that lower serum neuroserpin levels in the first 24 hours after stroke correlate with higher IL-6, ICAM-1, MMP-9, and fibronectin — all markers of inflammation and blood-brain barrier breakdown¹¹¹¹ lower serum neuroserpin levels in the first 24 hours after stroke correlate with higher IL-6, ICAM-1, MMP-9, and fibronectin — all markers of inflammation and blood-brain barrier breakdown
suggesting that impaired neuroserpin function worsens acute stroke injury.

Practical Actions

Given the emerging and ancestry-specific nature of this evidence, rs6797312 is best understood as a candidate risk modifier rather than an established risk factor. For women of European ancestry, particularly those with additional conventional stroke risk factors, this variant may warrant consideration in overall risk stratification. The most actionable response is awareness of conventional modifiable stroke risk factors — atrial fibrillation, hypertension, migraine with aura, and oral contraceptive use in the context of other risk factors — because these interact with heritable cerebrovascular vulnerabilities. There are no neuroserpin-specific therapies available for clinical use; ongoing research into neuroserpin-delivering extracellular vesicles and recombinant neuroserpin as stroke neuroprotectants is experimental only.

Interactions

Neuroserpin operates in the same fibrinolytic pathway as PAI-1 (SERPINE1, rs1799889) and tPA (PLAT). Variants that alter PAI-1 activity could compound with reduced neuroserpin activity — for example, a PAI-1 4G/5G promoter variant reducing systemic fibrinolysis combined with reduced neuroserpin CNS protection might stack stroke risk through complementary mechanisms. Formal compound-genotype studies have not been conducted. The rs6797312 signal in young women raises the possibility of a sex-hormone-mediated interaction, as estrogen modulates both tPA expression and neuroserpin activity in neurons, but this has not been directly tested in genetic association studies.